Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|9|1|39-49

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.9, Iss.1, 2003-01, pp. : 39-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Resistance of fibrogenic responses to glucocorticoid and 2-methoxyestradiol in bleomycin-induced lung fibrosis in mice

By Langenbach Shenna Y.   Wheaton Ben J.   Fernandes Darren J.   Jones Catherine   Sutherland Tara E.   Wraith Bronwyn C.   Harris Trudi   Schuliga Michael J.   McLean Catriona   Stewart Alastair G.  

Canadian Journal of Physiology and Pharmacology, Vol. 85, Iss. 7, 2007-07 ,pp. : 727-738

NRC Research Press

Access to resources Recommend Favorite

Effects on Cytokines and Histology by Treatment with the Ace Inhibitor Captopril and the Antioxidant Retinoic Acid in the Monocrotaline Model of Experimentally Induced Lung Fibrosis

By  

Current Pharmaceutical Design, Vol. 13, Iss. 13, 2007-05 ,pp. : 1327-1333

Bentham Science Publishers

Access to resources Recommend Favorite

Old drugs up for re-evaluation in Italy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat

By Tuncer Ilyas   Ozbek Hanefi   Ugras Serdar   Bayram Irfan  

Experimental and Toxicologic Pathology, Vol. 55, Iss. 2-3, 2003-09 ,pp. : 159-166

Urban & Fischer

Access to resources Recommend Favorite

Cellular Players in Lung Fibrosis

By  

Current Pharmaceutical Design, Vol. 18, Iss. 27, 2012-09 ,pp. : 4093-4102

Bentham Science Publishers

Access to resources Recommend Favorite